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A B S T R A C T   
SARS-CoV-2 viral contagion has given rise to a worldwide pandemic. Although most children experience minor 
symptoms from SARS-CoV-2 infection, some have severe complications including Multisystem Inflammatory 
Syndrome in Children. Neuroblastoma patients may be at higher risk of severe infection as treatment requires 
immunocompromising chemotherapy and SARS-CoV-2 has demonstrated tropism for nervous cells. To date, 
there is no sufficient epidemiological data on neuroblastoma patients with SARS-CoV-2. Therefore, we evaluated 
datasets of non-SARS-CoV-2 infected neuroblastoma patients to assess for key genes involved with SARS-CoV-2 
infection as possible neuroblastoma prognostic and infection biomarkers. We hypothesized that ACE2, CD147, 
PPIA and PPIB, which are associated with viral-cell entry, are potential biomarkers for poor prognosis neuro-
blastoma and SARS-CoV-2 infection. 
We have analysed three publicly available neuroblastoma gene expression datasets to understand the specific 
molecular susceptibilities that high-risk neuroblastoma patients have to the virus. Gene Expression Omnibus 
(GEO) GSE49711 and GEO GSE62564 are the microarray and RNA-Seq data, respectively, from 498 neuro-
blastoma samples published as part of the Sequencing Quality Control initiative. TARGET, contains microarray 
data from 249 samples and is part of the Therapeutically Applicable Research to Generate Effective Treatments 
(TARGET) initiative. ACE2, CD147, PPIA and PPIB were identified through their involvement in both SARS-CoV- 
2 infection and cancer pathogenesis. 
In-depth statistical analysis using Kaplan-Meier, differential gene expression, and Cox multivariate regression 
analysis, demonstrated that overexpression of ACE2, CD147, PPIA and PPIB is significantly associated with poor- 
prognosis neuroblastoma samples. These results were seen in the presence of amplified MYCN, unfavourable 
tumour histology and in patients older than 18 months of age. Previously, we have shown that high levels of the 
nerve growth factor receptor NTRK1 together with low levels of the phosphatase PTPN6 and TP53 are associated 
with increased relapse-free survival of neuroblastoma patients. Interestingly, low levels of expression of ACE2, 
CD147, PPIA and PPIB are associated with this NTRK1-PTPN6-TP53 module, suggesting that low expression 
levels of these genes are associated with good prognosis. These findings have implications for clinical care and 
therapeutic treatment. The upregulation of ACE2, CD147, PPIA and PPIB in poor-prognosis neuroblastoma 
samples suggests that these patients may be at higher risk of severe SARS-CoV-2 infection. Importantly, our 
findings reveal ACE2, CD147, PPIA and PPIB as potential biomarkers and therapeutic targets for neuroblastoma.   
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1. Introduction 
High infection rate of SARS-CoV-2 virus has resulted in a global 
pandemic [1]. Severe infection elicits a hyper inflammatory response 
[2] and pose a risk to immunocompromised patients with pre-existing 
medical conditions [2]. Therefore, there is a need to understand the 
detrimental effects of SARS-CoV-2 infection on paediatric cancer pa-
tients, such as those with neuroblastoma. 
Although mortality due to SARS-CoV-2 infection in children is low 
and most children experience minor symptoms from infection [3], some 
develop neurological complications including encephalopathy, seizure 
and peripheral nerve palsies [4], or the life threatening Multisystem 
Inflammatory Syndrome in Children [3]. Since close to 90% of neuro-
blastoma diagnosis is primarily in the first 12–24 months of age [5], 
patients could be at a greater risk of SARS-CoV-2 infection, as children 
under 5-years of age are more likely to develop severe symptoms [3,6]. 
Moreover, patients may be at higher-risk of infection due to their 
immunocompromised status as a result of chemotherapy treatment and 
specific molecular susceptibilities to the virus caused by cancer [6]. 
Since SARS-CoV-2 contagion will, most likely, continue in the future, it 
is critical to understand whether neuroblastoma patients are at higher 
risk of severe infection. 
Neuroblastomas are tumours of sympathoadrenergic origin and the 
most frequent neoplasms of infancy [5]. Long-term survival with 
high-risk type of neuroblastoma is poor. Prognosis depends upon patient 
age and tumour biology [5]. Good-prognosis neuroblastomas which are 
differentiated and have favourable cytogenetics [5,7], express high 
levels of the nerve growth factor (NGF) receptor tyrosine-kinase NTRK1 
[7,8], whereas poor-prognosis tumours which are poorly differentiated, 
contain segmental chromosomal-abnormalities (SCA) such as 17p gain, 
1q and 11q loss, and have MYCN-amplification [7,8], express the neu-
rotrophin receptor tyrosine-kinase NTRK2 [7,8]. On NGF-stimulation, 
NTRK1 is activated by tyrosine phosphorylation at positions 490, 670, 
674, 675, and 785 [8]. This induces signalling promoting differentiation 
of neuroblastoma cells [8]. Neuroblastomas are characterised by dis-
playing high cell heterogeneity, which is reflected in their clinical pre-
sentation and poor outcomes [5,7,8]. The varied location of the tumours 
together with complex histopathology and biological characteristics 
makes neuroblastoma difficult to treat with high-risk patients having 
poor survival outcomes [5]. 
We have demonstrated that the tumour suppressor TP53 represses 
expression of the phosphatase PTPN6, resulting in activation of NTRK1 
[9]. Furthermore, we have shown that this type of NTRK1-activation is 
independently and significantly associated with 5-year relapse free 
survival (RFS) of children with neuroblastoma including patients with 
high-risk type tumours [10]. This module is independently associated 
with RFS in the presence of MYCN-amplification, SCA and histology 
status. Therefore, suggesting that together NTRK1, wild-type TP53 and 
low levels of PTPN6 expression could be a predictive biomarker of good 
prognosis for neuroblastoma [10]. 
ACE2, an enzyme belonging to the renin-angiotensin-system that 
cleaves Angiotensin I to Angiotensin II, behaves as the major cell-entry 
receptor for SARS-CoV-2 [11]. ACE2 binds the SARS-CoV-2 S1 subunit of 
the Spike (S) protein, facilitating cell-entry [11]. ACE2 expression is 
decreased in breast-cancer and hepatocellular carcinoma [12,13]. 
Upregulation of the ACE2/Ang-(1–7)/Mas axis inhibits breast-cancer 
cell migration and invasion [14]. However, ACE2 upregulation is asso-
ciated with poor-survival in lung adenocarcinoma [15,16] and the 
ACE2/Ang-(1–7)/Mas axis promotes migration and invasion of renal 
carcinoma cells [17]. These findings suggest that ACE2 plays a cancer 
specific role. 
CD147, a cell-surface receptor and interleukin signalling mediator 
[18], interacts with SARS-CoV-2 S protein to mediate viral infection 
[18]. Loss of CD147 inhibits increased SARS-CoV-2 viral load, and 
expression of CD147, in non-susceptible cells, facilitates viral-entry 
[19]. In breast- and colorectal-cancer high CD147 expression is 
associated with poor disease free survival (DFS) [19]. CD147 is 
expressed in neuroblastoma exosomes [20] and high expression is 
associated with undifferentiated tumours [21]. 
PPIA and PPIB which are peptidyl-prolyl cis-trans isomerases 
involved in inflammation [22], facilitate viral-entry of SARS-CoV by 
interacting with CD147 [23]. They interact with nsp-1of SARS-CoV and 
are incorporated into the viral capsid and then released, enabling further 
virus binding to CD147 and subsequent infection of CD147-expressing 
cells [23]. They are overexpressed in glioblastoma multiforme and 
non-small-cell lung carcinoma [24]. PPIA correlates with poor outcome 
in gastric-cancer [24] and PPIB promotes cell proliferation and invasion 
in gastric and non-small cell lung cancer [25]. 
Given the heterogeneous histological nature of neuroblastoma, the 
identification of neuroblastoma biomarkers is of key significance for 
patient outcome. Our aim is to identify potential biomarkers that could 
be used as prognostic indicators and potential treatment targets for 
neuroblastoma. We have hypothesized that ACE2, CD147, PPIA, and 
PPIB which are involved in SARS-CoV-2 viral cell-entry are potential 
biomarkers for neuroblastoma and SARS-CoV-2 infection. 
2. Methods 
2.1. Datasets 
Three neuroblastoma gene expression datasets of non-SARS-Cov2 
infected patients were assessed. Gene Expression Omnibus (GEO) data-
base, accession number GSE49711, 498 samples of Agilent customized 4 
× 44K oligonucleotide microarray data were downloaded, of which 492 
have event free survival (EFS) data and MYCN amplification status, were 
analysed. For validation, Illumina HiSeq 2000 RNA-Seq data from the 
same samples was downloaded from GEO GSE62564 and analysed in the 
same fashion. Microarray data was measured as the log-base-2 of the 
number of bases aligned in the gene, and the RNA-Seq data was 
measured in log2RPM. (GEO, https://www.ncbi.nlm.nih.gov/geo/). 
The third dataset contained Affymetrix Exon-ST microarray data from 
249 samples analysed as part of the Therapeutically Applicable Research 
to Generate Effective Treatments (TARGET) initiative and was down-
loaded from cBioportal as z-scores (https://software.broadinstitute.or 
g/cancer/cga/target) In this dataset, 243 samples had event free sur-
vival (EFS) data and MYCN amplification status. All datasets contained 
tumour histology and age at diagnosis information. Clinical character-
istics of each dataset can be seen in Supplementary Table 1. 
GSE49711 and GSE62564 datasets were non-normally distributed 
due to a peak of values at 0 for the microarray data (GSE49711) and at 
less than − 6 for the RNA-Seq data (GSE62564). These non-normal peaks 
are most likely due to undetected reads. Since z-scores must be calcu-
lated from normally distributed data, the non-normal scores were 
removed. Z-scores were calculated by comparing the expression of each 
gene in each sample to the expression of the gene across all samples. 
Gene expression in samples stratified by MYCN amplification, age at 
diagnosis, tumour histology, and NTRK1-TP53-PTPN6 module presence, 
was assessed by comparing mean z-scores using the independent t-test. 
For the NTRK1-TP53-PTPN6 module, samples with TP53 and PTPN6 z- 
scores < 0 and NTRK1 z-scores > 0 were considered as having the 
presence of the module whereas samples with TP53 and PTPN6 z-scores 
> 0 and NTRK1 z-scores < 0 were considered as having absence of the 
module. This approach is consistent with published studies character-
ising this module [10]. 
2.2. Statistical analysis 
Z-scores were used to categorise gene expression into low, moderate 
or high. A z-score of less than − 0.5 indicated low, − 0.5 to 0.5 indicated 
moderate and greater than 0.5 indicated high expression, respectively. 
The Kaplan-Meier method was used to calculate estimates of cumulative 
survival probabilities (survival function). Plots were generated and the 
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log-rank statistic was used to determine the statistical significance of the 
differences between the survival functions. EFS was defined as the time, 
in days/years, between treatment or the start of a study, and the event 
was defined as relapse, progression, death or study end. A Cox regression 
hazard model was generated and multivariate analysis was performed. 
Stratification by MYCN amplification, tumour histology, age at diag-
nosis and presence of the NTRK1-PTPN6-TP53 module was undertaken. 
The statistical significance threshold was taken at 95% confidence in-
terval and a P = 0.05 or less. 
3. Results 
3.1. ACE2, CD147, PPIA and PPIB expression and association with event 
free survival 
To assess whether expression of ACE2, CD147, PPIA, or PPIB could 
have prognostic value in neuroblastoma, multivariate analysis was un-
dertaken in 492 samples obtained from the GSE49711 dataset. Although 
GSE49711 was used for the main analysis, results were confirmed with 
the GSE62564 and TARGET datasets. 
Multivariate analysis (Table 1) showed that high and moderate ACE2 
(hazard ratio (HR) = 1.48, P = 0.05 and HR = 1.58, P = 0.03, respec-
tively), high CD147 (HR = 2.13, P = < 0.005) and high and moderate 
PPIA expression (HR = 2.74, P < 0.005 and HR = 2.01, P < 0.005, 
respectively) were independently associated with poor-neuroblastoma 
survival. High PPIB expression trended towards poor-survival (HR =
1.29, P = 0.28). Interestingly, removal of PPIA from the model 
Table 1 
Multivariate analysis a of 492 neuroblastoma samples expressing ACE2, CD147, 
PPIA and PPIB (GSE49711).  
Variable Hazard ratio P b 
ACE2 
Low 1  
Moderate 1.58 .03 
High 1.48 .05 
CD147 
Low 1  
Moderate 1.46 .10 
High 2.13 <.005 
PPIA 
Low 1  
Moderate 2.01 <.005 
High 2.74 <.005 
PPIB 
Low 1  
Moderate 0.85 .46 
High 1.29 .28  
a Multivariate analysis Cox regression model. 
b P values lower than 0.05 were deemed significant. 
Fig. 1. Kaplan-Meier survival curves and Box plots (GSE49711) for 492 neuroblastoma samples expressing ACE2, CD147, PPIA, and PPIB. For each gene analysed, 
samples were stratified into low, medium and high expression groups. 
Kaplan-Meier curves were plotted for each group, and survival distributions curves were compared with the log-rank test. Samples with high expression show 
significantly decreased EFS when compared to samples with low expression A) ACE2, B) CD147, C) PPIA and D) PPIB 
Samples were stratified into groups by MYCN amplification and Box plots were plotted using EFS data. Independent t-tests and log-rank tests were used to determine 
significance E) ACE2, F) CD147, G) PPIA and H) PPIB. 
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demonstrated that high PPIB expression was significantly associated 
with poor-survival (HR = 1.68, P = 0.02) (Supplementary Table 2) 
suggesting that the prognostic effects of PPIB relies on its correlation 
with PPIA. 
Multivariate analysis was undertaken in samples stratified by MYCN 
amplification, age at diagnosis, tumour histology and the NTRK1- 
PTPN6-TP53 module. Analysis adjusted for MYCN amplification, a key 
poor prognosis marker [7], showed moderate ACE2 (HR = 1.51, P =
0.04), high CD147 (HR = 1.97, P = 0.01) and high and moderate PPIA 
expression (HR = 2.30, P < 0.005 and HR = 1.85, P = 0.01, respectively) 
significantly associated with poor prognosis independent of MYCN 
amplification (Supplementary Table 3). Neuroblastomas are classified as 
differentiating (with ganglionic characteristics) or undifferentiated 
(with neuroblastic characteristics) [5]. Adjustment by tumour histology 
showed that only moderate and high PPIA expression was significantly 
associated with poor-survival independent of tumour histology (HR =
1.65, P = 0.04 and HR = 2.33, P < 0.005, respectively) (Supplementary 
Table 4). Since age at diagnosis affects patient outcome [5], expression 
was analysed in patients younger and older than 18 months of age. 
Moderate ACE2 (HR = 1.56, P = 0.03), high CD147 (HR = 1.99, P =
0.01), and moderate and high PPIA expression (HR = 1.80, P = 0.01 and 
HR = 2.27, P < 0.005, respectively) was significantly associated with 
poor-survival independent of age at diagnosis (Supplementary Table 5). 
These results were supported by Kaplan-Meier analysis which 
showed significant separation in survival outcome between high, mod-
erate and low expression of ACE2, CD147, PPIA or PPIB (Fig. 1A–D). It 
was estimated that patients with high ACE2 expression had a 59.4% 
probability of 5-year event free survival (EFS) with a median survival- 
time of over 5-years, whereas low expression had a 73.3% probability 
of 5-year EFS with a median survival-time of over 5-years. For CD147 
high levels had a 38.1% probability of 5-year EFS with a median 
survival-time of 1.83 years, whereas with low expression the probability 
of survival increased to 81.6% with a median survival-time of over 5- 
years. For PPIA and PPIB patients with high expression had a 36.9% 
Fig. 2. Kaplan-Meir survival curves for 492 neuroblastoma samples expressing high levels of NTRK1 together with low levels of PTPN6 and TP53 (presence of 
module) or low levels of NTRK1 together with high levels of PTPN6 and TP53 (absence of module). Survival distributions curves were compared with the log-rank 
test A) GEO GSE49711 dataset and B) TARGET dataset. 
Box plots were plotted for both datasets using EFS data. Independent t-tests and log-rank tests were used to determine significance C) GEO GSE49711 dataset and D) 
TARGET dataset. 
Samples were stratified by presence of the NTRK1-PTPN6-TP53 module (GEO GSE49711 dataset). Box plots were plotted using EFS data. Independent t-tests and log- 
rank tests were used to determine significance E) ACE2, F) CD147, G) PPIA and H) PPIB. In samples with the NTRK1-PTPN6-TP53 module, low expression of ACE2, 
CD147, PPIA or PPIB show significantly increased EFS. 
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and 37.7%, respectively, probability of survival with a median survival- 
time of 1.8 and 2.23 years, respectively, whereas with low expression 
survival increased to 82.6% and 75.1%, with a median survival-time of 
over 5-years, respectively. 
Gene expression was analysed for association with MYCN amplifi-
cation, age at diagnosis and tumour histology. Samples were stratified 
based on the presence of each prognostic marker, and expression of each 
gene was compared between the stratified groups using the independent 
t-test (Fig. 1E–H). MYCN amplification was significantly associated with 
upregulation of ACE2, CD147, PPIA and PPIB in GSE49711. Similar 
results were obtained with GSE62564 dataset. PPIA was seen signifi-
cantly associated in TARGET (Supplementary Table 6). Unfavourable 
tumour histology was associated with upregulation of CD147, PPIA, and 
PPIB (Supplementary Fig. 1 A-D) in GSE49711 and GSE62564 (Sup-
plementary Table 7). Significant association remained for PPIA and PPIB 
in TARGET (Supplementary Table 7). Samples from patients older than 
18 months of age were associated with upregulation of all four genes 
(Supplementary Fig. 1 E-H) in GSE49711. Similar results were observed 
with GSE62564 (Supplementary Table 8). In TARGET, results remained 
significant for PPIB (Supplementary Table 8). 
3.2. ACE2, CD147, PPIA and PPIB expression and association with 
NTRK1-PTPN6-TP53 
To verify that samples expressing high levels of NTRK1 together with 
low levels of PTPN6 and TP53 are indicative of good prognosis as pre-
viously demonstrated by our laboratory [10], EFS was analysed using 
the Kaplan Meier method and an independent t-test. It was estimated 
that patients with NTRK1-PTPN6-TP53 expression had an 81.7% prob-
ability of 5-year EFS with a median survival-time of over 5-years, 
whereas lack of expression had a 56.2% probability of 5-year EFS with 
a median survival-time of 3.4 years in GSE49711 (Fig. 2 A). Similar 
results were obtained with TARGET (Fig. 2 B). It was estimated that 
patients with NTRK1-PTPN6-TP53 expression had a 61.8% probability 
of 5-year EFS with a median survival-time of over 5-years, whereas lack 
of expression had a 32.8% probability of 5-year EFS with a median 
survival-time of 1.7 years. Therefore, verifying association of the mod-
ule with prolonged EFS [10]. 
Multivariate analysis of ACE2, CD147, PPIA and PPIB in samples 
expressing NTRK1-PTPN6-TP53 showed this module significantly asso-
ciated with good-prognosis independent of ACE2, CD147, PPIA and PPIB 
expression (HR = 0.47, P = < 0.005) (Table 2). Furthermore, in 
GSE49711, NTRK1-PTPN6-TP53 was significantly associated with 
downregulation of ACE2, CD147, PPIA and PPIB (Fig. 2E–H). These 
results remained significant for GSE62564 and in the case of the 
TARGET dataset for PPIA and PPIB (Supplementary Table 9). 
It is important to indicate that stratification by SCA was not under-
taken. From the three datasets, only TARGET had information regarding 
SCA in the form of 59 samples. This low sample number was not sta-
tistically powerful to carry out the analysis. 
4. Discussion 
Together, these results show that ACE2, CD147, PPIA and PPIB 
which are genes involved in viral-entry of SARS-CoV-2, are upregulated 
and significantly associated with poor-prognosis neuroblastomas with 
MYCN amplification, unfavourable histology and in patients older than 
18 months of age. Moreover, their expression is downregulated in tu-
mours expressing NTRK1-PTPN6-TP53. This strongly suggests that poor- 
prognosis patients may be at a higher risk of SARS-CoV-2 infection when 
compared to those expressing NTRK1-PTPN6-TP53. Furthermore, the 
upregulation of ACE2, CD147, PPIA and PPIB may not only render poor- 
prognosis neuroblastoma patients more vulnerable to infection, but may 
also lead to increased viral load and more severe infection. 
These findings are supported by our preliminary identification of 
enriched-gene-clusters and enriched-pathways in prognosis-related 
clusters of neuroblastoma samples (using the TARGET dataset), with 
potential to interact with SARS-CoV-2 proteins. Results showed that in 
potential poor-prognosis clusters PI3K-AKT-mTOR signalling and 
CD147, PPIA, PPIB and NTRK1 could be implicated in interactions with 
the SARS-CoV NSP3 protein. NSP3 is of relevance as SARS-CoV NSP3 
shares 94% sequence homology with SARS-CoV-2 NSP3 [26]. The NSP3 
protein has immuno-evasive properties by inhibiting interferon signal-
ling and preventing attack from the host’s immune system [27]. Inter-
estingly, interferon signalling was also prevalent in interactions 
investigated in poor prognosis S-type and Mesenchymal neuroblastoma 
cell lineages. However, these results need further investigation due to 
the complex and heterogeneous nature of neuroblastoma. 
Since SARS-CoV-2 infection is likely to persist in the future, these 
findings may have implications for patient care. CD147 participates in 
neuroblastoma tumour growth and metastasis [28]. Inhibition of CD147 
is, therefore, a potential treatment strategy for slowing tumour growth. 
Evidence demonstrates that inhibition of CD147 in glioblastoma can 
reduce tumour cell invasion [29]. Meplazumab, a biological drug which 
blocks CD147 on the surface of Vero E6 cells and inhibits SARS-CoV-2 
replication [30], could potentially treat SARS-CoV-2 infection and 
neuroblastoma. 
Although ACE2 has been associated with SARS-CoV cell-entry [31], 
and CD147 and PPIA facilitate infection of Human Immunodeficiency 
Virus (HIV-1) and genome replication of Hepatitis C Virus (HCV) [32, 
33], it is the statistically significant relationship between ACE2, CD147, 
PPIA and PPIB as a result of the analysis of the neuroblastoma datasets 
that strongly emphasises their importance as potential neuroblastoma 
prognostic markers. 
Together these results enhance the knowledge regarding neuroblas-
toma patient risk to severe SARS-CoV-2 infection. Although studies have 
assessed SARS-CoV-2 infection rates in paediatric cancer patients [6], to 
date, few have specifically focused on neuroblastoma. Given that 
treatment of high-risk neuroblastoma needs further development, our 
findings of ACE2, CD147 and PPIA as significantly independent prog-
nostic markers should be considered as potential treatment targets. 
Furthermore, drugs developed to target ACE2, CD147 and PPIA could be 
repositioned for neuroblastoma treatment. 
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Table 2 
Multivariate analysis a of 492 neuroblastoma samples expressing ACE2, CD147, 
PPIA and PPIB adjusted for the NTRK1-PTPN6-TP53 module (GSE49711).  
Variable Hazard ratio P b 
NTRK1-PTPN6-TP53 module 
Absent 1  
Present 0.47 <.005 
ACE2 
Low 1  
Moderate 1.50 .05 
High 1.36 .13 
CD147 
Low 1  
Moderate 1.41 .14 
High 2.17 <.005 
PPIA 
Low 1  
Moderate 1.98 <.005 
High 2.61 <.005 
PPIB 
Low 1  
Moderate 0.81 .31 
High 1.14 .57  
a Multivariate analysis Cox regression model. 
b P values lower than 0.05 were deemed significant. 
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